The U.S. Food and Drug Administration (FDA) approved a supplemental efficacy application for Keytruda (pembrolizumab) on November 21, 2025. This approval, identified as BLA 125514 S-188, signifies an expansion or update to the drug's existing efficacy profile.
Background
Pembrolizumab, marketed as Keytruda, is a widely recognized immunotherapy drug. Supplemental applications to the FDA are common regulatory processes that allow manufacturers to update or expand the approved uses of an already-marketed drug. These applications can cover new indications, patient populations, dosing regimens, or modifications to the existing label based on new clinical data. A supplemental efficacy application specifically means that new data has been submitted and reviewed by the FDA, demonstrating additional or improved effectiveness for pembrolizumab in a particular context. The sponsor for this application is Merck Sharp Dohme.
What this means
This FDA approval for a supplemental efficacy application for Keytruda (pembrolizumab) provides clinicians and patients with updated information regarding the drug's demonstrated effectiveness. While the specific details of the expanded indication or population are not provided in the immediate approval notice, such an approval typically means that Keytruda is now approved for an additional use or in a broader patient group where its efficacy has been scientifically established. This can lead to new treatment options for patients and expand the utility of pembrolizumab in clinical practice. Healthcare providers will need to consult the updated prescribing information to understand the full scope of this new approval and its implications for patient care.
Source
This information is based on an official record from the U.S. Food and Drug Administration (FDA). The approval for Keytruda (pembrolizumab) supplemental application BLA 125514 S-188 was recorded on November 21, 2025, and is accessible via the FDA's Drugs@FDA database at accessdata.fda.gov.